Member Info for David1951c

AIM is a joke and there is much less institutional and fund investment partly due to the volatility in share prices, which is a real turn off even for large companies in London - look at Wood Group today. The low SP here is a good entry or top up point. Company must be worth multiples of £15m Mcap.

More good news. Making progress in a major market is another promising development and if Lipid is shown to provide the benefits in Saxony then there is much potential for other regions in Germany. It may not produce great revenue initially but further roll out would be material.

Yes. Ondo could easily have raised more to drive expansion at an even greater pace. As an existing shareholder I would very much liked to have had the opportunity AND have warrants. The raise was not unexpected (post 5 May)and it makes sense to do this when the company is expanding rapidly.

A further update on how expansion in Sweden (and other European markets) is going would be very welcome.

Soon after midday SP is down nearly 10% and according to trades showing on here the sales amount to £21k and buys £15k. Please can someone explain how minimal trades can impact the pricing so disproportionately. Is there a guide to what seems to be a methodology which is not fit for purpose.

I tried to add 25k but cannot get a price on HL at the moment. Suggests a buyer in the background?

Acuere thanks - still no news which is the key next step. Delays and lack of information / updates have understandably caused a decline in SP. Possibly a buying opportunity but still risks remain until FDA approval is achieved.

Another positive announcement and undoubtedly Zen have a significant range of products with material differential. Real sales volumes have not been disclosed so not possible to ascertain revenue to the company.

The main issue as an investment case is whether more working capital will be required before sales cover all costs and positive cash flow is achieved. Otherwise a fund raise may be required to give a breathing space to get there. Can Zen find a cornerstone investor to help them?

Very encouraging as LF comprises 23 regional companies and when additional members start to roll out the others are likely to do the same if the first companies prove how good it is. Further news on this and other markets progress will demonstrate the value to the wider insurance market.
My only concern is whether Ondo will need more capital to fully drive the expansion as potential is immense for a company with Mcap of around £10m currently. The next financial statements will be v. important as the company is relatively new in its current shape. I do not think Ondo would get the big deals without showing their capability to support the expansion.

Thanks. I thought FDA submission was additional to CPT code and CLIA approval already confirmed. This company has great potential and with more visibility on revenue and further expansion, it should do very well.

H1 report in September said Filing of FDA Pre-Submission for Cardio inCode® (Cardiovascular Disease Genetic Risk Score) for the onset of cardiovascular disease. Progressive discussions with the FDA in advance of the forthcoming 510K regulatory submission. The submission is expected to be filed with the FDA over the coming weeks." It seems overdue but if granted would give a huge boost to the company and SP.
Invested here quite a bit and hope news will be good and soon.

PDM selling is not a good sign as it implies lack of confidence in the company and will as in this case lower the SP. The reasons for the large sale have been explained in RNS and in fact the JD holding has increased. Some largish sales today also undermine any expected SP recovery.
When CPH2 get the issues sorted and the orders fulfilled it should showcase the company. In the meantime there still seems to be a technology risk. Probably a good time to buy in H1 as success in hydrogen production would be mean lift off. Reassuring to note that cash position is still very good and will see the company through next 18 months by when revenue should be rising steeply.

.... this company as there is little information or history to go on. Results for 31.8.2022 look positive and numerous collaborations with significant potential. Cash was £1.8m but there are no indications as to actual performance. The last results included the usual going concern phrase and hopefully the significant holders are still invested.
The latest tie up with WNS is significant and it is doubtful they would partner with a company like Ondo without full due diligence on technical, financial and operational aspects. They will be confident in Ondo's capability to deliver. Other customers like Admiral, Hiscox, LB and LF will have done the same.
Ondo should provide a business update for y/e 28.2.23 and how major partnerships are progressing. Advancing the roll out with LF's regional businesses in Sweden will also be material.

There seem to be concerns about numbers and net profitability but with the increased level of cash and falling debt, this looks another possible take over target. Medica has just been snapped up. SPs on AIM are often appalling and more investors will be selling up with better values in many other markets.

Very promising with lots of potential but it will take time for the number of installations and revenue to become apparent.
Also needed is confirmation that more of LF's regional businesses are coming on board.
In due course hoping the company will give quarterly updates on volumes.

More than a month ago I thought a trading update would be coming as it had in previous years.
The delay bothered me then and does now because usually AIM companies are quick to announce good news and delay bad news. My concern is still the immediate cash position and if more funds will need to be raised for the short term. If LOOP can get through this then with £5m Mcap the value of the company and SP should begin to recover.

Not sure anything has gone wrong as the updates in RNSs on 17th Feb seemed positive. However purely based on revenue, EBITA and cash the valuation / Mcap may seem high and possibly a fund raise might be necessary to support the plans and growth.
AIM is an unforgiving place right now and many growth companies' share prices struggle - look at Kin & Carta. It is a great shame that those companies with excellent prospects and growth plans are poorly treated in the current market conditions. No company should list on AIM when the conditions and SP volatility are an investors' nightmare
AIM pricing methodology is also an issue. Today £28k of share sales on ENSI has caused a Mcap drop of £6m - nonsensical.

The key issue is funding and especially for phase 3. As mentioned in OBI's 2021 results released last May, funding will be required in 2023. As a PI the threat of dilution through an equity fund raise must be factored in to investment decisions.
As with DEST the potential is huge but how to fund and complete P3 is a critical question.

In September GENI RNS said the "filing of FDA Pre-Submission for Cardio inCode for the onset of cardiovascular disease. Progressive discussions with the FDA in advance of the forthcoming 510K regulatory submission. The submission is expected to be filed with the FDA over the coming weeks."
Hopefully that will happen very soon. Also a business update to year end would be welcome.
This company has a lot of potential and seems well funded for 2023/24. With about 80% in the hands of Significant Shareholders and Directors the position seems quite promising.

Having had a closer look at this there is in my view a clear high risk and potential high reward with LOOP.
The big cons are lack of profitability (high cost base?), low cash and some debt. The big question is will cash last until profitability is restored.
On the other hand Mcap of £6m is tiny so a lot of potential upside if they get through the next 6 months. The customer base is growing and they have a great network covering 67 countries.
So the next trading update is critical. Not long to wait.

In last two years the update was on 15.2.2022 and 8.2.2021 so another one should be due in next seven days or so.
It is hard to call but most news has been positive on contract side but finances look shaky on cash and debt side. Raising at 5p means those shareholders are well under but the bigger question is whether it is enough to keep the business afloat.
Having made a good profit at the peak and then reinvested some of that at 20p it is a gamble but have bought 100k shares at 3.52 - showing as a sell.

There have been a number of large (100k shares) sells today which has dragged down the SP. News should arrive soon as the pre-close trading update RNS was issued on 25 Jan last year.